Bethesda, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress. “We have made significant progress across our pipeline this...
finance News
Stamford, Conn. — GeneDx Holdings Corp. (Nasdaq: WGS) (“GeneDx” or the “Company”), a leader in delivering improved health outcomes through genomic and clinical insights, reported its financial results for the fourth quarter and full year ended December 31, 2022. “Entering 2023 with a new corporate strategy and a focus on...
Genomenon, Inc.®, an AI-driven genomics company, today announced a collaboration with Alexion, AstraZeneca Rare Disease that will make critical information needed for the diagnosis and treatment for a set of rare diseases more readily accessible. The goal of this collaboration is to empower genetic testing labs with the data they need to...
SEATTLE – According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027). Key Trends and Analysis: The increasing incidence of myeloproliferative neoplasm is expected...
A new partnership combining AI and rare disease drug discovery with a patient-centered treatment network is seeking to unlock drug cures for the world’s most intractable diseases. AI-powered, patient-inspired technology company Healx – which is headquartered on Hills Road – has teamed up with US-based Mission: Cure, a non-profit coalition...
COPENHAGEN, Denmark and BOSTON – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the successful closing of a US$ 55M Series A financing. The investment was led by Novo Holdings, HealthCap and RA Capital Management. Benny Sorensen, MD, PhD, who served on Hemab’s Board...
Adult men with hemophilia B had annual health care costs that totaled more than 25-fold higher than matched controls, demonstrating the burden of this illness in research published in Blood Advances. The study authors used a claims-based algorithm to identify 454 male patients with hemophilia B and compared them to 454...
Bedford, Mass. — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments. “We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome,...
DEERFIELD, Ill. – Horizon Therapeutics (Nasdaq: HZNP) and the Cubs announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGen Pharma, an OPKO Health Company (Nasdaq: OPK) in Waterford, Ireland. The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser,...